

| Date Launched | Regimen Name on NCCP website  | Tumour Group     | Regimen Number |
|---------------|---|------------------|----------------|
| 01/10/2019    | Tivozanib Therapy   | Genitourinary    | 564            |
| 18/10/2019    | Brentuximab vedotin and Bendamustine Therapy  | Lymphoma         | 529            |
| 23/10/2019    | Ribociclib Therapy-28 day   | Breast           | 525            |
| 22/11/2019    | Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy   | Lung             | 579            |
|               | Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy   | Lung             | 568            |
|               | Pembrolizumab, PEMEtrexed and CISplatin Therapy   | Lung             | 569            |
| 06/12/2019    | Capecitabine 825mg/m <sup>2</sup> and RT-7 day  | Gastrointestinal | 586            |
|               | Topotecan Oral Monotherapy  | Lung             | 587            |
| 08/01/2020    | Apalutamide therapy   | Genitourinary    | 574            |
|               | Abiraterone 1000mg and Prednisolone 5mg Therapy   | Genitourinary    | 577            |
|               | Pembrolizumab 200mg and Axitinib Therapy  | Genitourinary    | 583            |
| 19/03/2020    | Durvalumab Monotherapy  | Lung             | 576            |
|               | CISplatin, Infusional 5-Fluorouracil and Radiation Therapy  | Gastrointestinal | 594            |
| 06/04/2020    | Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day | Myeloma          | 598            |
| 09/04/2020    | Atezolizumab 1680mg Monotherapy – 28 Day  | Genitourinary    | 593            |
|               |   | Lung             | 593            |